Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of SCT650C in adults with hidradenitis suppurativa
CTR20263775Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing SCT650C with Placebo (2 arms). Primary endpoint: HiSCR75 at Week 16. Started Jan 2026; status: active.
02
Drugs
SCT650C
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on CTR20263775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263775.